Olukotun AY - Search Results

1

Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine.

Grossman R, Kuhn MJ, Maravilla K, Lee D, Schild H, Ethier R, Reiser M, Yuh WT, Olukotun AY. Grossman R, et al. Among authors: olukotun ay. Acad Radiol. 1998 Apr;5 Suppl 1:S154-5; discussion S156. doi: 10.1016/s1076-6332(98)80089-5. Acad Radiol. 1998. PMID: 9561068 Clinical Trial. No abstract available.

2

Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.

DeSimone D, Morris M, Rhoda C, Lucas T, Zielonka J, Olukotun A, Carvlin M. DeSimone D, et al. Invest Radiol. 1991 Nov;26 Suppl 1:S212-6; discussion S232-5. doi: 10.1097/00004424-199111001-00073. Invest Radiol. 1991. PMID: 1808133 Clinical Trial. No abstract available.

3

Safety of MR contrast media.

Olukotun AY. Olukotun AY. Radiology. 1994 May;191(2):584-5. doi: 10.1148/radiology.191.2.8153348. Radiology. 1994. PMID: 8153348 No abstract available.

4

Addressing cost-containment and cost-effectiveness in magnetic resonance contrast agent development.

Ashley RA, Carvlin MJ, Lucas TP, Olukotun AY. Ashley RA, et al. Among authors: olukotun ay. Invest Radiol. 1994 Jun;29 Suppl 2:S257-9. doi: 10.1097/00004424-199406001-00088. Invest Radiol. 1994. PMID: 7928250 Clinical Trial. No abstract available.

5

Safety of gadoteridol injection: U.S. clinical trial experience.

Olukotun AY, Parker JR, Meeks MJ, Lucas MA, Fowler DR, Lucas TR. Olukotun AY, et al. J Magn Reson Imaging. 1995 Jan-Feb;5(1):17-25. doi: 10.1002/jmri.1880050106. J Magn Reson Imaging. 1995. PMID: 7696805 Clinical Trial.

6

Phase I clinical evaluation of a new iron oxide MR contrast agent.

McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, Olukotun AY. McLachlan SJ, et al. Among authors: olukotun ay. J Magn Reson Imaging. 1994 May-Jun;4(3):301-7. doi: 10.1002/jmri.1880040313. J Magn Reson Imaging. 1994. PMID: 8061425 Clinical Trial.

7

Contrast media cost analysis--II.

Olukotun AY. Olukotun AY. J Am Coll Cardiol. 1994 Mar 1;23(3):826-7; author reply 827-8. doi: 10.1016/0735-1097(94)90777-3. J Am Coll Cardiol. 1994. PMID: 8113572 Free article. No abstract available.

8

Efficacy and safety of intravenous nadolol for supraventricular tachycardia.

Olukotun AY, Klein GJ. Olukotun AY, et al. Am J Cardiol. 1987 Aug 31;60(6):59D-62D. doi: 10.1016/0002-9149(87)90710-7. Am J Cardiol. 1987. PMID: 3630923 Clinical Trial.

9

Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias.

Saksena S, Klein GJ, Kowey PR, Calvo RA, Boccadamo R, Brown JE, Sharma AD, Gadhoke A, Olukotun AY. Saksena S, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Feb 1;59(4):307-12. doi: 10.1016/0002-9149(87)90804-6. Am J Cardiol. 1987. PMID: 3812280

10

Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting.

Khuri SF, Okike ON, Josa M, Vander Salm TJ, Assoussa S, Leone L, Silverman A, Siouffi S, Olukotun AY. Khuri SF, et al. Among authors: olukotun ay. Am J Cardiol. 1987 Aug 31;60(6):51D-58D. doi: 10.1016/0002-9149(87)90709-0. Am J Cardiol. 1987. PMID: 3498356 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page